Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

Article  PubMed  Google Scholar 

Golan T, Sella T, Margalit O, Amit U, Halpern N, Shacham-Shmueli E, et al. Short- and long-term survival in metastatic pancreatic adenocarcinoma, 1993–2013. J Natl Compr Cancer Netw. 2017;15(8):1022–7.

Article  Google Scholar 

Conroy T, Desseigne F, Ychou M, Bouchè O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.

Article  CAS  PubMed  Google Scholar 

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.

Article  Google Scholar 

Wang-Gillam A, Li C‑P, Bodoky G, Dean A, Shan Y‑S, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–57.

Article  CAS  PubMed  Google Scholar 

ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, et al. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol. 2018;9(3):e151–e60.

Article  Google Scholar 

Rochefort P, Lardy-Cleaud A, Sarabi M, Desseigne F, Cattey-Javouhey A, de la Fouchardiere C. Long-term survivors in metastatic pancreatic ductal adenocarcinoma: a retrospective and matched pair analysis. Oncologist. 2019;4:1543–8.

Article  Google Scholar 

Kowalczyk M, Mandelson MT, Lin BS‑L, Picozzi VJ. Metastatic pancreatic cancer (MPC): contrast of short-(STS) and long-term(LTS) survivor characteristics. J Clin Oncol. 2018;36(suppl 4S):abstract 415.

Article  Google Scholar 

Gao Y, Wang WJ, Zhi Q, Shen M, Jiang M, Bian X, et al. Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer. Oncotarget. 2017;8:88835–44.

Article  PubMed  PubMed Central  Google Scholar 

Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, et al. nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107(2):dju413.

Article  PubMed  Google Scholar 

Colloca GA, Venturino A, Guarneri D. Neutrophil count kinetics during the first cycle of chemotherapy predicts the outcome of patients with locally advanced or metastatic pancreatic cancer. Asia Pac J Clin Oncol. 2020;16(4):247–53.

Article  PubMed  Google Scholar 

van der Sijde F, Vietsch EE, Mustafa DAM, Besselinj MG, Koerkamp BG, van Eijck CHJ. Circulating biomarkers for prediction of objective response to chemotherapy in pancreatic cancer patients. Cancers. 2019;11:93.

Article  PubMed  PubMed Central  Google Scholar 

Yoo T, Lee WJ, Woo SM, Kim TH, Han SS, Park SJ, et al. Pretreatment carbohydrate antigen 19‑9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;81:e623–e30.

Article  CAS  PubMed  Google Scholar 

Cannistrà M, Ruggiero M, Zullo A, Serafini S, Grande R, Nardo B. Metastases of pancreatic adenocarcinoma: a systematic review of literature and a new functional concept. Int J Surg. 2015;21(1):S15–S21.

Article  PubMed  Google Scholar 

Zheng B, Ohuchida K, Yan Z, Okumura T, Ohtsuka T, Nakamura M. Primary recurrence in the lung is related to favorable prognosis in patients with pancreatic cancer and postoperative recurrence. World J Surg. 2017;41:2858–66.

Article  PubMed  Google Scholar 

Wangjam T, Zhang Z, Zhou XC, Lyer L, Faisal F, Soares KC, et al. Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget. 2015;6(34):36903–10.

Article  PubMed  PubMed Central  Google Scholar 

Jr Uson PLS, D’Avila Sampaio Tolentino F, Montes Santos V, Rother ET, Maluf FC. The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies. PLoS ONE. 2020; https://doi.org/10.1371/journal.pone.0230060.

Article  PubMed  Google Scholar 

Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, Mehrabi A, et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a Surveillance Epidemiology and End Results database analysis. World J Gastroenterol. 2017;23(10):1872–8.

Article  PubMed  PubMed Central  Google Scholar